nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

14.08.2023 | Research

Construction and validation of an efferocytosis-related prognostic signature in lung adenocarcinoma

verfasst von: Jian Liu, Li Wei

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 16/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

Accumulating evidence highlights the potential significance of efferocytosis in tumor progression. This study is directed towards the construction of a prognostic risk model for lung adenocarcinoma (LUAD), grounded on efferocytosis-related genes (ERGs).

Methods

Employing LASSO-COX regression analysis, a risk-prognostic model was formulated, centered on seven ERGs. Concurrently, a nomogram was established that incorporated patient clinical features and risk scores. The predictive accuracy of the risk model and the nomogram was substantiated via external validation sets. The landscapes of immune infiltration and genetic mutation were evaluated for high- and low-risk groups, with the expression of seven key genes validated through RT-PCR.

Results

Our findings reveal that the high-risk group displayed considerably inferior survival outcomes in comparison to the low-risk group. A diminished abundance of immune cell infiltrates and a higher prevalence of gene mutations characterized the high-risk group. Genes with high expression were markedly enriched in pathways related to cell proliferation. The superior predictive performance of the risk model and nomogram was adequately substantiated by the external validation sets (GSE31210, GSE30219, and GSE50081). In addition, we discerned several potential therapeutic drugs demonstrating different sensitivities across patient risk groups. The differential expression of seven central genes was confirmed in A549, H1299, and BEAS-2B cell lines.

Conclusion

The constructed risk model and nomogram display high accuracy in predicting the survival and immune landscape of LUAD patients, thus providing invaluable prognostic tools in clinical scenarios.

Nur mit Berechtigung zugänglich

Banerjee HN, Bartlett V, Krauss C, Aurelius C, Johnston K, Hedley J, Verma M (2021) Efferocytosis and the Story of “Find Me,” “Eat Me,” and “Don’t Eat Me” signaling in the tumor microenvironment. Adv Exp Med Biol 1329:153–162. https://doi.org/10.1007/978-3-030-73119-9_8CrossRefPubMed

Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, Holko M, Yefanov A, Lee H, Zhang N, Robertson CL, Serova N, Davis S, Soboleva A (2013) NCBI GEO: archive for functional genomics data sets--update. Nucleic acids Res 41(Database issue): D991–D995. https://doi.org/10.1093/nar/gks1193

Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, Vonderheide RH, Pittet MJ, Jain RK, Zou W, Howcroft TK, Woodhouse EC, Weinberg RA, Krummel MF (2018) Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 24(5):541–550. https://doi.org/10.1038/s41591-018-0014-xCrossRefPubMedPubMedCentral

Birge RB, Boeltz S, Kumar S, Carlson J, Wanderley J, Calianese D, Barcinski M, Brekken RA, Huang X, Hutchins JT, Freimark B, Empig C, Mercer J, Schroit AJ, Schett G, Herrmann M (2016) Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer. Cell Death Differ 23(6):962–978. https://doi.org/10.1038/cdd.2016.11CrossRefPubMedPubMedCentral

Boada-Romero E, Martinez J, Heckmann BL, Green DR (2020) The clearance of dead cells by efferocytosis. Nat Rev Mol Cell Biol 21(7):398–414. https://doi.org/10.1038/s41580-020-0232-1CrossRefPubMedPubMedCentral

Chaudhary S, Patidar A, Dhiman A, Chaubey GK, Dilawari R, Talukdar S, Modanwal R, Raje M (2021) Exposure of a specific pleioform of multifunctional glyceraldehyde 3-phosphate dehydrogenase initiates CD14-dependent clearance of apoptotic cells. Cell Death Dis 12(10):892. https://doi.org/10.1038/s41419-021-04168-8CrossRefPubMedPubMedCentral

Chen W, Li L, Wang J, Zhang R, Zhang T, Wu Y, Wang S, Xing D (2021) The ABCA1-efferocytosis axis: A new strategy to protect against atherosclerosis. Clinica Chimica Acta Int J Clin Chem 518:1–8. https://doi.org/10.1016/j.cca.2021.02.025CrossRef

Cheng A, Xu T, You W, Wang T, Zhang D, Guo H, Zhang H, Pan X, Wang Y, Liu L, Zhang K, Shi J, Yao X, Guo J, Yang Z (2023) A mitotic NADPH upsurge promotes chromosome segregation and tumour progression in aneuploid cancer cells. Nat Metab. https://doi.org/10.1038/s42255-023-00832-9CrossRefPubMedPubMedCentral

Der SD, Sykes J, Pintilie M, Zhu CQ, Strumpf D, Liu N, Jurisica I, Shepherd FA, Tsao MS (2014) Validation of a histology-independent prognostic gene signature for early-stage, non-small-cell lung cancer including stage IA patients. J Thoracic Oncol 9(1):59–64. https://doi.org/10.1097/JTO.0000000000000042CrossRef

Doran AC, Yurdagul A Jr, Tabas I (2020) Efferocytosis in health and disease. Nat Rev Immunol 20(4):254–267. https://doi.org/10.1038/s41577-019-0240-6CrossRefPubMed

Duma N, Santana-Davila R, Molina JR (2019) Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc 94(8):1623–1640. https://doi.org/10.1016/j.mayocp.2019.01.01CrossRefPubMed

Friggeri A, Yang Y, Banerjee S, Park YJ, Liu G, Abraham E (2010) HMGB1 inhibits macrophage activity in efferocytosis through binding to the alphavbeta3-integrin. Am J Physiol Cell Physiol 299(6):C1267–C1276. https://doi.org/10.1152/ajpcell.00152.2010CrossRefPubMedPubMedCentral

Ismail OZ, Sriranganathan S, Zhang X, Bonventre JV, Zervos AS, Gunaratnam L (2018) Tctex-1, a novel interaction partner of Kidney Injury Molecule-1, is required for efferocytosis. J Cell Physiol 233(10):6877–6895. https://doi.org/10.1002/jcp.26578CrossRefPubMedPubMedCentral

Jiang G, Song C, Wang X, Xu Y, Li H, He Z, Cai Y, Zheng M, Mao W (2023) The multi-omics analysis identifies a novel cuproptosis-anoikis-related gene signature in prognosis and immune infiltration characterization of LUAD. Heliyon 9(3):e14091. https://doi.org/10.1016/j.heliyon.2023.e14091CrossRefPubMedPubMedCentral

Jin Y, Pan Y, Zheng S, Liu Y, Xu J, Peng Y, Zhang Z, Wang Y, Xiong Y, Xu L, Mu K, Chen S, Zheng F, Yuan Y, Fu J (2022) Inactivation of EGLN3 hydroxylase facilitates Erk3 degradation via autophagy and impedes lung cancer growth. Oncogene 41(12):1752–1766. https://doi.org/10.1038/s41388-022-02203-2CrossRefPubMedPubMedCentral

Kasikara C, Schilperoort M, Gerlach B, Xue C, Wang X, Zheng Z, Kuriakose G, Dorweiler B, Zhang H, Fredman G, Saleheen D, Reilly MP, Tabas I (2021) Deficiency of macrophage PHACTR1 impairs efferocytosis and promotes atherosclerotic plaque necrosis. J Clin Investig 131(8):e145275. https://doi.org/10.1172/JCI145275CrossRefPubMedPubMedCentral

Kawano M, Nagata S (2018) Efferocytosis and autoimmune disease. Int Immunol 30(12):551–558. https://doi.org/10.1093/intimm/dxy055CrossRefPubMedPubMedCentral

Kumar S, Birge RB (2016) Efferocytosis. Curr Biol 26(13):R558–R559. https://doi.org/10.1016/j.cub.2016.01.059CrossRefPubMed

Li X, Dai Z, Wu X, Zhang N, Zhang H, Wang Z, Zhang X, Liang X, Luo P, Zhang J, Liu Z, Zhou Y, Cheng Q, Chang R (2022) The comprehensive analysis identified an autophagy signature for the prognosis and the immunotherapy efficiency prediction in LUAD. Front Immunol 13:749241. https://doi.org/10.3389/fimmu.2022.749241CrossRefPubMedPubMedCentral

Li G, Javed M, Rasool R, Abdel-Maksoud MA, Mubarak AS, Studenik CR, Narayanan J, Atuahene SA, Aufy M, Cao K (2023) A pan-cancer analysis of HAVCR1 with a focus on diagnostic, prognostic and immunological roles in human cancers. Am J Translat Res 15(3):1590–1606

Lin J, Xu A, Jin J, Zhang M, Lou J, Qian C, Zhu J, Wang Y, Yang Z, Li X, Yu W, Liu B, Tao H (2022) MerTK-mediated efferocytosis promotes immune tolerance and tumor progression in osteosarcoma through enhancing M2 polarization and PD-L1 expression. Oncoimmunology 11(1):2024941. https://doi.org/10.1080/2162402X.2021.2024941CrossRefPubMedPubMedCentral

Liu M, O’Connor RS, Trefely S, Graham K, Snyder NW, Beatty GL (2019) Metabolic rewiring of macrophages by CpG potentiates clearance of cancer cells and overcomes tumor-expressed CD47-mediated ‘don’t-eat-me’ signal. Nat Immunol 20(3):265–275. https://doi.org/10.1038/s41590-018-0292-yCrossRefPubMedPubMedCentral

Lv B, Wang Y, Ma D, Cheng W, Liu J, Yong T, Chen H, Wang C (2022) Immunotherapy: Reshape the Tumor Immune Microenvironment. Front Immunol 13:844142. https://doi.org/10.3389/fimmu.2022.844142CrossRefPubMedPubMedCentral

Maeser D, Gruener RF, Huang RS (2021) oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Briefings Bioinform. https://doi.org/10.1093/bib/bbab260CrossRef

Maruoka M, Zhang P, Mori H, Imanishi E, Packwood DM, Harada H, Kosako H, Suzuki J (2021) Caspase cleavage releases a nuclear protein fragment that stimulates phospholipid scrambling at the plasma membrane. Mol Cell 81(7):1397-1410.e9. https://doi.org/10.1016/j.molcel.2021.02.025CrossRefPubMed

Maschalidi S, Mehrotra P, Keçeli BN, De Cleene HKL, Lecomte K, Van der Cruyssen R, Janssen P, Pinney J, van Loo G, Elewaut D, Massie A, Hoste E, Ravichandran KS (2022) Targeting SLC7A11 improves efferocytosis by dendritic cells and wound healing in diabetes. Nature 606(7915):776–784. https://doi.org/10.1038/s41586-022-04754-6CrossRefPubMed

Mehrotra P, Ravichandran KS (2022) Drugging the efferocytosis process: concepts and opportunities. Nat Rev Drug Discovery 21(8):601–620. https://doi.org/10.1038/s41573-022-00470-yCrossRefPubMed

Meier LA, Faragher JL, Osinski V, Auger JL, Voeller R, Marath A, Binstadt BA (2022) CD47 Promotes Autoimmune Valvular Carditis by Impairing Macrophage Efferocytosis and Enhancing Cytokine Production. J Immunol (Baltimore, Md: 1950), 208(12): 2643–2651. https://doi.org/10.4049/jimmunol.2100903

Miller M, Hanna N (2021) Advances in systemic therapy for non-small cell lung cancer. BMJ (Clinical research ed.), 375:n2363. https://doi.org/10.1136/bmj.n2363

Noone PM, Reddy SP (2021) Recent advances in dead cell clearance during acute lung injury and repair. Faculty Rev 10:33. https://doi.org/10.12703/r/10-33

Okayama H, Kohno T, Ishii Y, Shimada Y, Shiraishi K, Iwakawa R, Furuta K, Tsuta K, Shibata T, Yamamoto S, Watanabe S, Sakamoto H, Kumamoto K, Takenoshita S, Gotoh N, Mizuno H, Sarai A, Kawano S, Yamaguchi R, Miyano S, Yokota J (2012) Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative LUADs. Cancer Res 72(1):100–111. https://doi.org/10.1158/0008-5472.CAN-11-1403CrossRefPubMed

Razi S, Yaghmoorian Khojini J, Kargarijam F, Panahi S, Tahershamsi Z, Tajbakhsh A, Gheibihayat SM (2023) Macrophage efferocytosis in health and disease. Cell Biochem Funct 41(2):152–165. https://doi.org/10.1002/cbf.3780CrossRefPubMed

Rousseaux S, Debernardi A, Jacquiau B, Vitte AL, Vesin A, Nagy-Mignotte H, Moro-Sibilot D, Brichon PY, Lantuejoul S, Hainaut P, Laffaire J, de Reyniès A, Beer DG, Timsit JF, Brambilla C, Brambilla E, Khochbin S (2013) Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci Translat Med 5(186):186ra66. https://doi.org/10.1126/scitranslmed.3005723CrossRef

Ruiz-Cordero R, Devine WP (2020) Targeted therapy and checkpoint immunotherapy in lung cancer. Surg Pathol Clin 13(1):17–33. https://doi.org/10.1016/j.path.2019.11.002CrossRefPubMed

Seguin L, Durandy M, Feral CC (2022) LUAD tumor origin: a guide for personalized medicine. Cancers 14(7):1759. https://doi.org/10.3390/cancers14071759CrossRefPubMedPubMedCentral

Shi L, Tan X, Liu X, Yu J, Bota-Rabassedas N, Niu Y, Luo J, Xi Y, Zong C, Creighton CJ, Glenn JS, Wang J, Kurie JM (2021) Addiction to Golgi-resident PI4P synthesis in chromosome 1q21.3-amplified LUAD cells. Proceedings of the National Academy of Sciences of the United States of America 118(25):e2023537118. https://doi.org/10.1073/pnas.2023537118CrossRefPubMedPubMedCentral

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA 71(3), 209–249. https://doi.org/10.3322/caac.21660

Tajbakhsh A, Rezaee M, Barreto GE, Moallem SA, Henney NC, Sahebkar A (2020) The role of nuclear factors as “Find-Me”/alarmin signals and immunostimulation in defective efferocytosis and related disorders. Int Immunopharmacol 80:106134. https://doi.org/10.1016/j.intimp.2019.106134CrossRefPubMed

Tavernari D, Battistello E, Dheilly E, Petruzzella AS, Mina M, Sordet-Dessimoz J, Peters S, Krueger T, Gfeller D, Riggi N, Oricchio E, Letovanec I, Ciriello G (2021) Nongenetic evolution drives LUAD spatial heterogeneity and progression. Cancer Discov 11(6):1490–1507. https://doi.org/10.1158/2159-8290.CD-20-1274CrossRefPubMed

Tian L, Choi SC, Murakami Y, Allen J, Morse HC 3rd, Qi CF, Krzewski K, Coligan JE (2014) p85α recruitment by the CD300f phosphatidylserine receptor mediates apoptotic cell clearance required for autoimmunity suppression. Nat Commun 5:3146. https://doi.org/10.1038/ncomms4146CrossRefPubMed

Voss OH, Tian L, Murakami Y, Coligan JE, Krzewski K (2015) Emerging role of CD300 receptors in regulating myeloid cell efferocytosis. Mol Cell Oncol 2(4):e964625. https://doi.org/10.4161/23723548.2014.964625CrossRefPubMedPubMedCentral

Wang X, Shi D, Zhao D, Hu D (2020) Aberrant methylation and differential expression of SLC2A1, TNS4, GAPDH, ATP8A2, and CASZ1 are associated with the prognosis of LUAD. Biomed Res Int 2020:1807089. https://doi.org/10.1155/2020/1807089CrossRefPubMedPubMedCentral

Werfel TA (2022) Assessment of the immune response to tumor cell apoptosis and efferocytosis. Methods Mol Biol (Clifton N.J.), 2543:45–55. https://doi.org/10.1007/978-1-0716-2553-8_5

Werfel TA, Cook RS (2018) Efferocytosis in the tumor microenvironment. Semin Immunopathol 40(6):545–554. https://doi.org/10.1007/s00281-018-0698-5CrossRefPubMedPubMedCentral

Wu CH, Hwang MJ (2019) Risk stratification for LUAD on EGFR and TP53 mutation status, chemotherapy, and PD-L1 immunotherapy. Cancer Med 8(13):5850–5861. https://doi.org/10.1002/cam4.2492CrossRefPubMedPubMedCentral

Zeng D, Ye Z, Shen R, Yu G, Wu J, Xiong Y, Zhou R, Qiu W, Huang N, Sun L, Li X, Bin J, Liao Y, Shi M, Liao W (2021) IOBR: multi-omics immuno-oncology biological research to decode tumor microenvironment and signatures. Front Immunol 12:687975. https://doi.org/10.3389/fimmu.2021.687975CrossRefPubMedPubMedCentral

Zeng D, Hu Z, Yi Y, Valeria B, Shan G, Chen Z, Zhan C, Lin M, Lin Z, Wang Q (2021b) Differences in genetics and microenvironment of LUAD patients with or without TP53 mutation. BMC Pulm Med 21(1):316. https://doi.org/10.1186/s12890-021-01671-8CrossRefPubMedPubMedCentral

Zhang W, Li Y, Lyu J, Shi F, Kong Y, Sheng C, Wang S, Wang Q (2022) An aging-related signature predicts favorable outcome and immunogenicity in LUAD. Cancer Sci 113(3):891–903. https://doi.org/10.1111/cas.15254CrossRefPubMedPubMedCentral

Zhang Z, Zhu H, Wang X, Lin S, Ruan C, Wang Q (2023) A novel basement membrane-related gene signature for prognosis of LUADs. Comput Biol Med 154:106597. https://doi.org/10.1016/j.compbiomed.2023.106597CrossRefPubMed

Zhang QX, Yang Y, Yang H, Guo Q, Guo JL, Liu HS, Zhang J, Li D (2021) The roles of risk model based on the 3-XRCC genes in LUAD progression. Translat Cancer Res 10(10):4413–4431. https://doi.org/10.21037/tcr-21-1431

Titel: Construction and validation of an efferocytosis-related prognostic signature in lung adenocarcinoma
verfasst von: Jian Liu
Li Wei
Publikationsdatum: 14.08.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 16/2023
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-023-05251-7

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Construction and validation of an efferocytosis-related prognostic signature in lung adenocarcinoma

Abstract

Background

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

Antikörper mobilisiert Neutrophile gegen Krebs

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 16/2023

The combined signatures of G protein-coupled receptor family and immune landscape provide a prognostic and therapeutic biomarker in endometrial carcinoma

Identification and validation of a novel anoikis-related long non-coding RNA signature for pancreatic adenocarcinoma to predict the prognosis and immune response

Mesothelin-targeted CAR-T therapy combined with irinotecan for the treatment of solid cancer

A case of endobronchial metastasis of colon cancer mimics sarcoidosis, and a review of related literature

Repeat hepatectomy versus percutaneous ablation for recurrent hepatocellular carcinoma: emphasis on the impact of early or late recurrence

Genetically determined circulating resistin concentrations and risk of colorectal cancer: a two-sample Mendelian randomization study

Neu im Fachgebiet Onkologie

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

Antikörper mobilisiert Neutrophile gegen Krebs

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Update Onkologie